ClinicalTrials.gg
RecruitingNCT06934941Updated Apr 18, 2025

Phase 1 Single Ascending Dose Study

A Phase 1 interventional study of NM-101 and Placebo in Healthy Subjects, sponsored by Neuramedy Co. Ltd.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by Neuramedy Co. Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Nov 2024, registered Apr 2025).
  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Phase 1, double-blind, placebo-controlled, single-centre, single ascending dose escalation study to assess safety and tolerability of a monoclonal antibody, NM-101 in healthy volunteer subject and multiple system atrophy (MSA) patients.

Read the detailed description

Phase 1, double-blind, placebo-controlled, single-centre, single ascending dose escalation study to assess safety and tolerability of a monoclonal antibody, NM-101 in healthy volunteer subject and multiple system atrophy (MSA) patients.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Single Ascending Dose study
03

In context

Lead sponsor

Neuramedy Co. Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male Healthy subjects, 18 to 60 years of age and in good health with no abnormality identified on the medical history, physical examination or laboratory evaluation at screening
  2. Body weight≥ 45kg and between 18 - 30 kg/m2
  3. Normal blood pressure (systolic >90 and \<140 mmHg, diastolic >40 and \<90mmHg) and pulse rate 40-100bpm at screening visit. Blood pressure and pulse are measured after 3 minutes in supine position
  4. Baseline must be \<450msec for men and \<470msec for women
  5. Normal 12-lead at screening
  6. No clinically significant abnormal laboratory test values at screening
  7. No clinically significant findings on the clinical neurological and ophthalmic examinations at screening and at baseline
  8. Good venous access in both arms
  9. Willing to consent to participate in study prior to study specific screening procedures with the understanding that the subject has the right to withdraw from the study at any time without prejudice
  10. Female subject who is surgically sterile, is , or agrees to use a highly effective method of (2 methods strongly recommended) during the study and for 6 months after the dosing of NM-101.

Exclusion criteria

Exclusion Criteria:

  1. History of serious adverse reaction or to biological agents including immunoglobulins
  2. Presence or history of any allergy requiring acute or chronic treatment; seasonal allergic rhinitis can be permitted unless the subject is taking systemic medication (nasal spray or local treatments permitted). Subjects having drug or food allergies are also excluded.
  3. History of or inflammatory disease
  4. Clinically significant (i.e., active) cardiovascular disease (e.g., hypertension, arrhythmia, myocardial infarction, heart failure, long syndrome or other conditions causing prolongation of the QT/QT interval corrected with Fridericia's formula [QTcF]) prior to screening.
  5. History of cerebral vascular accident or stroke. Subjects having high risk of developing a stroke are also excluded.
  6. History or positive test results at screening for (HIV), ,
  7. Positive in tuberculosis screening test (Quantiferon test)
  8. Active infection within 4 weeks from screening and body temperature >38℃
  9. Active immunization within 3 months prior to dosing of NM-101
  10. History or clinically significant evidence of cardiovascular, endocrine (e.g. diabetes mellitus), respiratory, renal, hepatic, gastrointestinal, haematological neurologic, psychiatric or other disease
  11. Chronic symptoms of pronounced constipation or diarrhoea or conditions associated with total or partial obstruction of the urinary track
  12. History or presence of including solid tumors and hematologic malignancies except for basal cell and squamous cell carcinoma of the skin that had been completely excised and were considered cured with no evidence of disease ≥ 3 years
  13. Participation in a clinical study during the previous 24 weeks i.e. from completion of the previous study to the planned first administration of the current study
  14. Loss of >500mL blood including blood donation within 12 weeks prior to screening visit
  15. Intake more than 24 units of alcohol per week (1 unit=250mL of beer, 100mL of wine or 35mL of spirits)
  16. Smokers >5 cigarettes or the equivalent in tobacco daily. Must have been willing to abstain from using tobacco and tobacco-containing products for 72 hours prior to the dosing of NM-101 and during the inpatient monitoring period.
  17. Treatment with any prescription medication and/or over-the-counter products (excluding acetaminophen, hormone replacement therapy (HRT) and ) within 30 days prior to dosing of NM-101. Routine vitamin therapy is allowed.
  18. History of drug or alcohol abuse within the past 5 years, a positive urine drug test and/or a positive alcohol urine test at Screening visit
  19. Surgery other than minor cosmetic surgery and minor dental surgery within 3 months from the screening visit
  20. History of lumbar surgery for any reasons (e.g., herniated disc) or other to having al lumbar puncture (LP)
  21. Vigorous physical exercise 48 hours prior to screening
  22. Women with a positive pregnancy test at screening
  23. Women who are breast feeding
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    NM-101

    NM-101 iv

    Drug: NM-101

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugNM-101

    NM-101 IV versus placebo

    Also known as: Placebo

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. To determine the pharmacokinetic profile of NM-101 after a single iv infusion

    Peak plasma drug concentration (Cmax)

    Time frame: Pre-dose, 0, 0.5, 1, 2, 4, 6, 8, 12hour post-dose at Day 1 and Day 2, 3, 4, 8, 15, 22, 29 and week 6, 8, 12

  2. To determine the pharmacokinetic profile of NM-101 after a single iv infusion

    Area under the plasma concentration versus time curve (AUC) at steady-state and until last observation

    Time frame: Pre-dose, 0, 0.5, 1, 2, 4, 6, 8, 12hour post-dose at Day 1 and Day 2, 3, 4, 8, 15, 22, 29 and week 6, 8, 12

  3. To determine the pharmacokinetic profile of NM-101 after a single iv infusion

    Concentration at trough

    Time frame: Pre-dose, 0, 0.5, 1, 2, 4, 6, 8, 12hour post-dose at Day 1 and Day 2, 3, 4, 8, 15, 22, 29 and week 6, 8, 12

  4. To determine the pharmacokinetic profile of NM-101 after a single iv infusion

    Time to maximum drug concentration

    Time frame: Pre-dose, 0, 0.5, 1, 2, 4, 6, 8, 12hour post-dose at Day 1 and Day 2, 3, 4, 8, 15, 22, 29 and week 6, 8, 12

  5. To determine the pharmacokinetic profile of NM-101 after a single iv infusion

    half-life of drug

    Time frame: Pre-dose, 0, 0.5, 1, 2, 4, 6, 8, 12hour post-dose at Day 1 and Day 2, 3, 4, 8, 15, 22, 29 and week 6, 8, 12

  6. To determine the pharmacokinetic profile of NM-101 after a single iv infusion

    Volume distribution of drug

    Time frame: Pre-dose, 0, 0.5, 1, 2, 4, 6, 8, 12hour post-dose at Day 1 and Day 2, 3, 4, 8, 15, 22, 29 and week 6, 8, 12

  7. To determine the pharmacokinetic profile of NM-101 after a single iv infusion

    Clearance rate of drug

    Time frame: Pre-dose, 0, 0.5, 1, 2, 4, 6, 8, 12hour post-dose at Day 1 and Day 2, 3, 4, 8, 15, 22, 29 and week 6, 8, 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Oct 2025, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 18, 2025
StartActual
Nov 25, 2024
Primary completionEst.
Oct 30, 2025
CompletionEst.
Mar 30, 2026
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06934941
Lead sponsor
Neuramedy Co. Ltd.
Responsible party
Sponsor
First posted
Apr 18, 2025
Start date
Nov 25, 2024
Primary completion
Oct 30, 2025 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Apr 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion